Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients

AIDS

Volumn 21, Issue 9, 2007, Pages 1147-1155

  Loutfy, Mona R ^a,b   Raboud, Janet M ^b,c   Antoniou, Tony ^a,d   Kovacs, Colin ^a,b   Shen, Sandy ^c   Halpenny, Roberta ^a   Ellenor, Darlene ^a   Ezekiel, Davia ^a   Zhao, Alice ^a   Beninger, Francis ^e  

^a MAPLE LEAF MEDICAL CLINIC   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bio alcamid; Facial lipoatrophy; HIV; Polyalkylimide gel; Quality of life; Treatment

Indexed keywords

ADRENALIN; ANTIRETROVIRUS AGENT; CEFALEXIN; IMIDE; LEVOFLOXACIN; LIDOCAINE; POLYALKYLIMIDE; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANXIETY; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; ERYTHEMA; FACIAL LIPOATROPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIPOATROPHY; MALE; PAIN; PENICILLIN ALLERGY; PHOTOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN BRUISING; SKIN NECROSIS; SKIN NODULE; SKIN REDNESS; SKIN SWELLING;

ACRYLIC RESINS; ADULT; ANXIETY; DRUG ADMINISTRATION SCHEDULE; FACE; FEMALE; GELS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34248512901     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3281c6148d     Document Type: Article

References (21)

1. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader 2000; 10:546-550.
2. Oette M, Juretzko P, Kroidl A, Sagir A, Wettstein M, Siegrist J, et al. Lipodystrophy syndrome and self-assessment of well being and physical appearance in HIV-positive patients. AIDS Patient Care STDS 2002; 16:413-417.
3. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS 2005; 19(Suppl 4):S14-S21.
4. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15:2441-2444.
5. Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis 2005; 18:25-33.
6. Tai VW, Schambelan M, Algren H, Shayevich C, Mulligan K. Effects of recombinant human growth hormone on fat redistribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 2002; 35:1258-1262.
7. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001; 86:3480-3487.
8. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438.
9. Murphy R, Zhang J, Hafner R, Shevitz A, Tashima K, Yarasheski K, et al. Switching to a thymidine analog-sparing or nucleoside-sparing regimen improves lipoatrophy: 24 week results of a prospective randomized clinical trial. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA 22-25 February 2005 Abstract 45LB.
10. Moyle G, Sabin C, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A 48-week, randomized, open-label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virologic suppression on HAART. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA 22-25 February 2005; Boston, February 2005 Abstract 44LB.
11. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, et al. Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17:2471-2477.
12. Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5:82-87.
13. Engelhard P, Knies M. Safety and efficacy of New-Fill (polylactic acid) in the treatment of HIV-associated lipoatrophy of the face (HALF). In: XIVth International AIDS Conference. Barcelona, Spain 7-12 July 2002 Abstract WePeB6011.
14. Mest DR, Humble G. Safety and efficacy of intradermal poly-L-lactic acid (Sculptra) injections in patients with HIV-associated facial lipoatrophy [Abstract]. Antivir Ther 2004; 9:L36.
15. Pacini S, Ruggiero M, Morucci G, Cammarota N, Protopapa C, Gulisano M. Bio-Alcamid: a novelty for reconstructive and cosmetic surgery. It J Anat Embryol 2002; 107:209-214.
16. Protopapa C, Sito G, Caporale D, Cammarota N. Bio-Alcamid™ in drug-induced lipodystrophy. J Cosmet Laser Ther 2003; 5:226-230.
17. Treacy PJ, Goldberg DJ. Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs. Dermatol Surg 2006; 32:804-808.
18. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28:979-986.
19. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6:481-493.
20. Savard J, Laberge B, Gauthier JG, Ivers H, Bergeron MG. Evaluating anxiety and depression in HIV-infected patients. J Pers Assess 1998; 71:349-367.
21. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9:169-180.